Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Erratum: Sunwoo, S.-Y. et al. A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies. Vaccines 2018, 6(3), 64.

Sunwoo SY, Schotsaert M, Morozov I, Davis AS, Li Y, Lee J, McDowell C, Meade P, Nachbagauer R, García-Sastre A, Ma W, Krammer F, Richt JA.

Vaccines (Basel). 2018 Nov 27;6(4). pii: E80. doi: 10.3390/vaccines6040080.

2.

FACS-Mediated Isolation of Neuronal Cell Populations From Virus-Infected Human Embryonic Stem Cell-Derived Cerebral Organoid Cultures.

Janssens S, Schotsaert M, Manganaro L, Dejosez M, Simon V, García-Sastre A, Zwaka TP.

Curr Protoc Stem Cell Biol. 2019 Feb;48(1):e65. doi: 10.1002/cpsc.65. Epub 2018 Oct 24.

PMID:
30358129
3.

A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies.

Sunwoo SY, Schotsaert M, Morozov I, Davis AS, Li Y, Lee J, McDowell C, Meade P, Nachbagauer R, García-Sastre A, Ma W, Krammer F, Richt JA.

Vaccines (Basel). 2018 Sep 14;6(3). pii: E64. doi: 10.3390/vaccines6030064.

4.

Spatial-Temporal Lineage Restrictions of Embryonic p63+ Progenitors Establish Distinct Stem Cell Pools in Adult Airways.

Yang Y, Riccio P, Schotsaert M, Mori M, Lu J, Lee DK, García-Sastre A, Xu J, Cardoso WV.

Dev Cell. 2018 Mar 26;44(6):752-761.e4. doi: 10.1016/j.devcel.2018.03.001.

5.

Zika Virus Alters DNA Methylation of Neural Genes in an Organoid Model of the Developing Human Brain.

Janssens S, Schotsaert M, Karnik R, Balasubramaniam V, Dejosez M, Meissner A, García-Sastre A, Zwaka TP.

mSystems. 2018 Feb 6;3(1). pii: e00219-17. doi: 10.1128/mSystems.00219-17. eCollection 2018 Jan-Feb.

6.

Pandemic H1N1 influenza A viruses suppress immunogenic RIPK3-driven dendritic cell death.

Hartmann BM, Albrecht RA, Zaslavsky E, Nudelman G, Pincas H, Marjanovic N, Schotsaert M, Martínez-Romero C, Fenutria R, Ingram JP, Ramos I, Fernandez-Sesma A, Balachandran S, García-Sastre A, Sealfon SC.

Nat Commun. 2017 Dec 5;8(1):1931. doi: 10.1038/s41467-017-02035-9.

7.

Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Job ER, Schotsaert M, Ibañez LI, Smet A, Ysenbaert T, Roose K, Dai M, de Haan CAM, Kleanthous H, Vogel TU, Saelens X.

J Virol. 2018 Jan 30;92(4). pii: e01584-17. doi: 10.1128/JVI.01584-17. Print 2018 Feb 15.

8.

Inactivated influenza virus vaccines: the future of TIV and QIV.

Schotsaert M, García-Sastre A.

Curr Opin Virol. 2017 Apr;23:102-106. doi: 10.1016/j.coviro.2017.04.005. Epub 2017 May 12. Review.

9.

Contribution of the Purinergic Receptor P2X7 to Development of Lung Immunopathology during Influenza Virus Infection.

Leyva-Grado VH, Ermler ME, Schotsaert M, Gonzalez MG, Gillespie V, Lim JK, García-Sastre A.

MBio. 2017 Mar 28;8(2). pii: e00229-17. doi: 10.1128/mBio.00229-17.

10.

Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.

Van den Hoecke S, Ehrhardt K, Kolpe A, El Bakkouri K, Deng L, Grootaert H, Schoonooghe S, Smet A, Bentahir M, Roose K, Schotsaert M, Schepens B, Callewaert N, Nimmerjahn F, Staeheli P, Hengel H, Saelens X.

J Virol. 2017 Mar 13;91(7). pii: e02500-16. doi: 10.1128/JVI.02500-16. Print 2017 Apr 1.

11.

A High-Resolution Look at Influenza Virus Antigenic Drift.

Schotsaert M, García-Sastre A.

J Infect Dis. 2016 Oct 1;214(7):982. doi: 10.1093/infdis/jiw183. Epub 2016 May 6. No abstract available.

12.

Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.

Schotsaert M, Ysenbaert T, Smet A, Schepens B, Vanderschaeghe D, Stegalkina S, Vogel TU, Callewaert N, Fiers W, Saelens X.

Sci Rep. 2016 Apr 13;6:24402. doi: 10.1038/srep24402.

13.

Influenza-binding sialylated polymer coated gold nanoparticles prepared via RAFT polymerization and reductive amination.

Zhang Z, Schepens B, Nuhn L, Saelens X, Schotsaert M, Callewaert N, De Rycke R, Zhang Q, Moins S, Benali S, Mespouille L, Hoogenboom R, De Geest BG.

Chem Commun (Camb). 2016 Feb 25;52(16):3352-5. doi: 10.1039/c6cc00501b.

PMID:
26823186
14.

A GFP expressing influenza A virus to report in vivo tropism and protection by a matrix protein 2 ectodomain-specific monoclonal antibody.

De Baets S, Verhelst J, Van den Hoecke S, Smet A, Schotsaert M, Job ER, Roose K, Schepens B, Fiers W, Saelens X.

PLoS One. 2015 Mar 27;10(3):e0121491. doi: 10.1371/journal.pone.0121491. eCollection 2015.

15.

Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen.

Schepens B, Schotsaert M, Saelens X.

Immunotherapy. 2015;7(3):203-6. doi: 10.2217/imt.15.11. No abstract available.

16.

Influenza vaccines: a moving interdisciplinary field.

Schotsaert M, García-Sastre A.

Viruses. 2014 Oct 9;6(10):3809-26. doi: 10.3390/v6103809. Review.

17.

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein.

Schepens B, Sedeyn K, Vande Ginste L, De Baets S, Schotsaert M, Roose K, Houspie L, Van Ranst M, Gilbert B, van Rooijen N, Fiers W, Piedra P, Saelens X.

EMBO Mol Med. 2014 Nov;6(11):1436-54. doi: 10.15252/emmm.201404005.

18.

M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.

Ibañez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W, Saelens X.

PLoS One. 2013;8(3):e59081. doi: 10.1371/journal.pone.0059081. Epub 2013 Mar 18.

19.

Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice.

De Baets S, Schepens B, Sedeyn K, Schotsaert M, Roose K, Bogaert P, Fiers W, Saelens X.

J Virol. 2013 Mar;87(6):3314-23. doi: 10.1128/JVI.03019-12. Epub 2013 Jan 9.

20.

Influenza vaccines: T-cell responses deserve more attention.

Schotsaert M, Saelens X, Leroux-Roels G.

Expert Rev Vaccines. 2012 Aug;11(8):949-62. Review.

PMID:
23002976
21.

Natural and long-lasting cellular immune responses against influenza in the M2e-immune host.

Schotsaert M, Ysenbaert T, Neyt K, Ibañez LI, Bogaert P, Schepens B, Lambrecht BN, Fiers W, Saelens X.

Mucosal Immunol. 2013 Mar;6(2):276-87. doi: 10.1038/mi.2012.69. Epub 2012 Jul 18.

PMID:
22806098
22.

Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective.

De Filette M, Ysenbaert T, Roose K, Schotsaert M, Roels S, Goossens E, Schepens B, Fiers W, Saelens X.

J Gen Virol. 2011 Feb;92(Pt 2):301-6. doi: 10.1099/vir.0.027086-0. Epub 2010 Oct 21.

PMID:
20965983
23.

Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Schotsaert M, Ibañez LI, Fiers W, Saelens X.

J Biomed Biotechnol. 2010;2010:863985. doi: 10.1155/2010/863985. Epub 2010 May 24.

24.

M2e-based universal influenza A vaccine.

Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X.

Vaccine. 2009 Oct 23;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. Review.

PMID:
19840661
25.

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

Schotsaert M, De Filette M, Fiers W, Saelens X.

Expert Rev Vaccines. 2009 Apr;8(4):499-508. doi: 10.1586/erv.09.6. Review.

26.

Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine.

Coucke D, Schotsaert M, Libert C, Pringels E, Vervaet C, Foreman P, Saelens X, Remon JP.

Vaccine. 2009 Feb 18;27(8):1279-86. doi: 10.1016/j.vaccine.2008.12.013. Epub 2008 Dec 27.

PMID:
19114075
27.

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londoño-Arcila P, Fiers W, Saelens X.

Vaccine. 2008 Dec 2;26(51):6503-7. doi: 10.1016/j.vaccine.2008.09.038.

PMID:
18835315

Supplemental Content

Loading ...
Support Center